BridgeBio Pharma, Inc. Variable Lease, Cost
BridgeBio Pharma, Inc. (BBIO) reported Variable Lease, Cost of $937.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-10
- BridgeBio Pharma, Inc. variable lease, cost for the quarter ending 2026-06-30 was $937.00K, a 12.76% decline year-over-year.
- BridgeBio Pharma, Inc. variable lease, cost for the quarter ending 2026-03-31 was $780.00K, a 44.52% decline year-over-year.
- BridgeBio Pharma, Inc. variable lease, cost for the quarter ending 2025-12-31 was $595.00K, a 55.30% decline year-over-year.
- BridgeBio Pharma, Inc. variable lease, cost for the quarter ending 2025-09-30 was $1.34M, a 9.57% decline year-over-year.
- BridgeBio Pharma, Inc. variable lease, cost for fiscal 2025 was $4.42M, a 29.94% decline from fiscal 2024.
- BridgeBio Pharma, Inc. variable lease, cost for fiscal 2024 was $6.30M, a 7.88% decline from fiscal 2023.
- BridgeBio Pharma, Inc. variable lease, cost for fiscal 2023 was $6.84M, a 11.43% increase from fiscal 2022.
- BridgeBio Pharma, Inc. variable lease, cost for fiscal 2022 was $6.14M, a 44.76% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $937.00K 10-Q · filed 2026-08-10 | $1.72M 10-Q · filed 2026-08-10 | $2.31M derived: sum of 3 quarters · filed 2026-08-10 | $3.65M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $780.00K 10-Q · filed 2026-05-07 | $1.38M derived: sum of 2 quarters · filed 2026-05-07 | $2.72M derived: sum of 3 quarters · filed 2026-05-07 | $3.79M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $595.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.94M derived: sum of 2 quarters · filed 2026-02-24 | $3.01M derived: sum of 3 quarters · filed 2026-08-10 | $4.42M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.34M 10-Q · filed 2025-10-29 | $2.42M derived: sum of 2 quarters · filed 2026-08-10 | $3.82M 10-Q · filed 2025-10-29 | $5.15M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.07M 10-Q · filed 2026-08-10 | $2.48M 10-Q · filed 2026-08-10 | $3.81M derived: sum of 3 quarters · filed 2026-08-10 | $5.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.41M 10-Q · filed 2026-05-07 | $2.74M derived: sum of 2 quarters · filed 2026-05-07 | $4.22M derived: sum of 3 quarters · filed 2026-05-07 | $5.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.81M derived: sum of 2 quarters · filed 2026-02-24 | $4.29M derived: sum of 3 quarters · filed 2026-02-24 | $6.30M 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.48M 10-Q · filed 2025-10-29 | $2.96M derived: sum of 2 quarters · filed 2025-10-29 | $4.97M 10-Q · filed 2025-10-29 | $6.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.48M 10-Q · filed 2025-08-05 | $3.49M 10-Q · filed 2025-08-05 | $5.15M derived: sum of 3 quarters · filed 2026-02-24 | $6.92M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $2.01M 10-Q · filed 2025-04-29 | $3.67M derived: sum of 2 quarters · filed 2026-02-24 | $5.44M derived: sum of 3 quarters · filed 2026-02-24 | $7.14M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.43M derived: sum of 2 quarters · filed 2026-02-24 | $5.13M derived: sum of 3 quarters · filed 2026-02-24 | $6.84M 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.77M 10-Q · filed 2024-11-12 | $3.47M derived: sum of 2 quarters · filed 2024-11-12 | $5.19M 10-Q · filed 2024-11-12 | $6.70M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $1.70M 10-Q · filed 2024-08-01 | $3.42M 10-Q · filed 2024-08-01 | $4.93M derived: sum of 3 quarters · filed 2025-02-20 | $6.50M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $1.72M 10-Q · filed 2024-05-02 | $3.23M derived: sum of 2 quarters · filed 2025-02-20 | $4.79M derived: sum of 3 quarters · filed 2025-02-20 | $6.30M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.08M derived: sum of 2 quarters · filed 2025-02-20 | $4.58M derived: sum of 3 quarters · filed 2025-02-20 | $6.14M 10-K · filed 2025-02-20 |
| 2022-09-30 | $1.57M 10-Q · filed 2023-11-02 | $3.07M derived: sum of 2 quarters · filed 2023-11-02 | $4.63M 10-Q · filed 2023-11-02 | $6.04M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.51M 10-Q · filed 2023-08-03 | $3.06M 10-Q · filed 2023-08-03 | $4.48M derived: sum of 3 quarters · filed 2024-02-22 | $5.59M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.56M 10-Q · filed 2023-05-04 | $2.97M derived: sum of 2 quarters · filed 2024-02-22 | $4.08M derived: sum of 3 quarters · filed 2024-02-22 | $5.05M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.52M derived: sum of 2 quarters · filed 2024-02-22 | $3.49M derived: sum of 3 quarters · filed 2024-02-22 | $4.24M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.11M 10-Q · filed 2022-11-03 | $2.08M derived: sum of 2 quarters · filed 2022-11-03 | $2.83M 10-Q · filed 2022-11-03 | $3.10M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $969.00K 10-Q · filed 2022-08-04 | $1.72M 10-Q · filed 2022-08-04 | $1.99M derived: sum of 3 quarters · filed 2023-02-23 | $2.25M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $751.00K 10-Q · filed 2022-05-05 | $1.02M derived: sum of 2 quarters · filed 2023-02-23 | $1.28M derived: sum of 3 quarters · filed 2023-02-23 | $1.42M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $274.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $531.00K derived: sum of 2 quarters · filed 2023-02-23 | $673.00K derived: sum of 3 quarters · filed 2023-02-23 | $832.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $257.00K 10-Q · filed 2021-11-04 | $399.00K derived: sum of 2 quarters · filed 2021-11-04 | $558.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $142.00K 10-Q · filed 2021-08-05 | $301.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $159.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |